Gossamer bio announces seralutinib meets primary endpoint in phase 2 torrey study in pah

San diego--( business wire )--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results for the torrey phase 2 study of seralutinib in patients with pulmonary arterial hypertension (pah). seralutinib is a tyrosine kinase inhibitor targeting pdgfrΑ/Β, csf1r, and c-kit, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.
GOSS Ratings Summary
GOSS Quant Ranking